My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

84.08 -0.47 (-0.55%)
Streaming Delayed Price Updated: 1:24 PM EDT, Sep 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
22 23 Next >
Looking for growth without the hefty price tag? Consider NASDAQ:INCY.
Looking for growth without the hefty price tag? Consider INCYTE CORP (NASDAQ:INCY). 
Via Chartmill
Goldman Sachs Maintains Buy Rating for Incyte: Here's What You Need To Know
 
Via Benzinga
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
From Incyte
Via Business Wire
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Earnings Outlook For Incyte
 
Via Benzinga
Expert Ratings for Incyte
 
Via Benzinga
Analyst Ratings for Incyte
 
Via Benzinga
Incyte's Earnings Outlook
 
Via Benzinga
Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023
From Incyte
Via Business Wire
NASDAQ:INCY stands out as a stock that provides good value for the fundamentals it showcases.
INCYTE CORP (NASDAQ:INCY) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
From Incyte
Via Business Wire
Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
From Incyte
Via Business Wire
Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
From Incyte
Via Business Wire
New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients
From Incyte
Via Business Wire
Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity
From Incyte
Via Business Wire
Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
From Incyte
Via Business Wire
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
From Incyte
Via Business Wire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy. 
Via InvestorPlace
Pancreatic Cancer Battle Boosted by $200M VC Firm
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and... 
Via Benzinga
Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival
Both companies now sell treatments for myelofibrosis, a rare bone marrow cancer. 
Via Investor's Business Daily
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
Incyte's Jakafi Patent Expiry In 2028 Poses Challenge, Analyst Says New Treatments To Battle For Market Share
Incyte Corporation's (NASDAQ: INCY) Q2 adjusted EPS reached $0.99, compared to $1.01 posted a year ago. 
Via Benzinga
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte Corporation
Via Business Wire
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
From Incyte
Via Business Wire
Cathie Wood's Ark Invest Buys Spotify, Iridium Shares — Trims Tesla, Coinbase Holdings
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2023
 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.